Aurinia Pharmaceuticals’ (AUPH) “Overweight” Rating Reiterated at Cantor Fitzgerald

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a research note issued on Monday, Benzinga reports. They presently have a $10.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 36.99% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Stock Up 3.8 %

NASDAQ AUPH traded up $0.27 during trading hours on Monday, reaching $7.30. 485,097 shares of the company’s stock were exchanged, compared to its average volume of 1,722,479. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -16.98 and a beta of 1.44. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $10.05. The company’s 50-day moving average is $6.06 and its two-hundred day moving average is $5.55. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The business had revenue of $57.10 million during the quarter, compared to the consensus estimate of $54.25 million. During the same period last year, the business posted ($0.08) EPS. Aurinia Pharmaceuticals’s revenue was up 37.6% on a year-over-year basis. On average, analysts forecast that Aurinia Pharmaceuticals will post 0.13 EPS for the current fiscal year.

Insider Activity at Aurinia Pharmaceuticals

In related news, insider Scott Michael Habig sold 18,249 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the transaction, the insider now owns 456,338 shares in the company, valued at $2,423,154.78. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several hedge funds have recently modified their holdings of AUPH. Armistice Capital LLC lifted its position in Aurinia Pharmaceuticals by 57.7% during the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock valued at $85,729,000 after purchasing an additional 3,488,000 shares during the period. Goldman Sachs Group Inc. lifted its position in Aurinia Pharmaceuticals by 39.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,048,456 shares of the biotechnology company’s stock valued at $18,416,000 after buying an additional 576,120 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Aurinia Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock valued at $7,673,000 after acquiring an additional 21,119 shares during the period. Bank of New York Mellon Corp raised its position in Aurinia Pharmaceuticals by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock valued at $2,791,000 after purchasing an additional 77,510 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its position in shares of Aurinia Pharmaceuticals by 196.1% during the 1st quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock worth $1,750,000 after acquiring an additional 231,260 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.